Form 4: Supernus Pharmaceuticals Director Gemayel Acquires Stock Options and Restricted Stock Units

Director Georges Gemayel acquired stock options and restricted stock units in Supernus Pharmaceuticals on February 19, 2025.

Summary

• On February 19, 2025, Georges Gemayel, a director of Supernus Pharmaceuticals, acquired 7,296 stock options with an exercise price of $33.52, vesting on February 19, 2026, and expiring on February 19, 2035.
• Gemayel also acquired 4,475 restricted stock units (RSUs), which will be settled in common stock upon vesting on February 19, 2026.
• Following these transactions, Gemayel directly owns 13,315 shares of Supernus common stock, 7,296 stock options, and 4,475 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of options and RSUs could be seen as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options and RSUs by a director may signal confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Supernus Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, Gemayel, SUPN